Popular Articles

Allos Therapeutics Completes Enrollment In Randomized Phase 2b Trial Of Pralatrexate In Patients With Advanced Non-Small Cell Lung Cancer
Allos Therapeutics, Inc. (Nasdaq: ALTH) announced the completion of patient enrollment in the Company"s randomized Phase 2b clinical trial comparing pralatrexate to erlotinib (Tarceva«) in patients with Stage IIIB/IV non-small cell lung cancer (NSCLC) who are, or have been, cigarette smokers who have failed treatment with at least one prior platinum-based chemotherapy regimen.

American Society Of Hematology Awards Grants To Encourage Novel Medical Training Programs
The American Society of Hematology (ASH) announces that Ellis J. Neufeld, MD, PhD, of Harvard Medical School, Thomas Shea, MD, of University of North Carolina at Chapel Hill, and Alvin Schmaier, MD, of Case Western Reserve University in Cleveland, will each receive ASH"s Alternative Training Pathway Grant this July. The grant is awarded to selected training program directors to encourage the development and implementation of novel hematology-related training programs in recognition of the need for more clinicians and clinical/translational researchers in hematology-related disciplines.
News of the day
Role For Innate, Not Adaptive, Immunity Revealed By Autoinflammatory Disease Model
Researchers at the University of California, San Diego School of Medicine have developed the first mouse model for auto-inflammatory diseases, disorders that involve the over-activation of the body"s innate, primitive immune system. Their study, published early on-line in Cell Immunity on June 4, suggests that the innate - not adaptive - immune system drives auto-inflammatory diseases. The findings could open new therapeutic directions for research into disorders such as gout or inflammatory bowel disease.

Send email

Send email:
Your message:
Your name/organization:
Your E-mail:
Enter today\\'s date, 2 digits
(spam protection):